IP Library › Granted Patent US 12,325,709

Granted Patent B2

US 12,325,709 · App. 17/765,856 · Granted Jun 10, 2025

Cannabinoid derivatives

Inventors: Siawash Ahmar (Toronto, CA); Jung Yun Kim (Mississauga, CA); Ping Shan Lai (North York, CA); Jeffrey Alan Omeara (Halton Hills, CA); Quang Huy To (Hamilton, CA); Peter Martin Dove (Smiths Falls, CA)

Assignee: CANOPY GROWTH CORPORATION

C07D487/04 C07C233/18 C07C233/60 C07C235/58 C07C235/60 C07C235/62 C07C235/64 C07C235/88 C07C255/29 C07C271/16 C07C271/24 C07C271/34 C07C271/48 C07D203/18 C07D205/04 C07D207/16 C07D207/24 C07D209/08 C07D209/44 C07D213/40 C07D233/64 C07D239/26 C07D257/04 C07D261/08 C07D261/14 C07D263/32 C07D271/10 C07D295/192 C07D295/26

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 12,325,709
App. No.: 17/765,856
Granted: Jun 10, 2025
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

This disclosure relates to cannabinoid derivatives of Formula (I), wherein R4 or R7 is a carboxamide group, pharmaceutical compositions comprising these compounds and methods of using the cannabinoid derivatives. These compounds are potential cannabinoid receptor inhibitors, including CB1 and CB2 receptors.

Claims (450)

1. A compound having structural formula:

or an enantiomer, diastereomer, racemate, or tautomer thereof, or a pharmaceutically acceptable salt, solvate or hydrate of the compound, enantiomer, diastereomer, racemate, or tautomer, wherein

the

moiety is

R 1 is hydrogen, halo, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, —CO 2 H, —(C 0 -C 4 alkyl)-C(O)O(C 1 -C 6 alkyl), —(C 0 -C 4 alkyl)-OC(O)O—(C 1 -C 6 alkyl), —OR 1a , —(C 1 -C 4 alkyl)OR 1a , —SR 1a , —(C 1 -C 4 alkyl)SR 1a , —NR 1b R 1c , —(C 1 -C 4 alkyl)NR 1b R 1c , —(C 1 -C 4 alkyl)C(O)NR 1b R 1c , —(C 0 -C 4 alkyl)-aryl, —(C 0 -C 4 alkyl)-heteroaryl, —(C 0 -C 4 alkyl)-cycloalkyl, —(C 0 -C 4 alkyl)-heterocycloalkyl, or oxo when attached to a ring of appropriate saturation, wherein

R 1a , R 1b , and R 1c are independently hydrogen, C 1 -C 4 alkyl, or —C(O)(C 1 -C 4 ) alkyl;

R 2 is hydrogen, halo, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, —CO 2 H, —(C 0 -C 4 alkyl)-C(O)O(C 1 -C 6 alkyl), —(C 0 -C 4 alkyl)-OC(O)O—(C 1 -C 6 alkyl), —OR 2a , —(C 1 -C 4 alkyl)OR 2a , —SR 2a , —(C 1 -C 4 alkyl)SR 2a , —NR 2b R 2c , —(C 1 -C 4 alkyl)NR 2b R 2c , —(C 1 -C 4 alkyl)C(O)NR 2b R 2c , —(C 0 -C 4 alkyl)-aryl, —(C 0 -C 4 alkyl)-heteroaryl, —(C 0 -C 4 alkyl)-cycloalkyl, —(C 0 -C 4 alkyl)-heterocycloalkyl, or oxo when attached to a ring of appropriate saturation, wherein

R 2a , R 2b , and R 2c are independently hydrogen, C 1 -C 4 alkyl, or —C(O)(C 1 -C 4 ) alkyl;

R 3 is C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, —(OCH 2 CH 2 ) 0-6 O(C 1 -C 8 alkyl), —(C 0 -C 4 alkyl)-NR 3a R 3b , —(C 0 -C 4 alkyl)-aryl, —(C 0 -C 4 alkyl)-heteroaryl, —(C 0 -C 4 alkyl)-cycloalkyl or —(C 0 -C 4 alkyl)-heterocycloalkyl, wherein R 3a and R 3b are each independently hydrogen or C 1 -C 6 alkyl;

R 4 is hydrogen,

wherein

Q 1 is O or S;

R 4a is hydrogen, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, —OR 4c , —(C 1 , C 2 or C 4 alkyl)OR 4c , —(C 0 -C 4 alkyl)-C(O)(C 1 -C 4 alkyl), —(C 0 -C 4 alkyl)-C(O)O(R 4c ), —(C 0 -C 4 alkyl)CN, —(CH 2 CH 2 O) 0-6 (C 1 -C 8 alkyl), —(CH 2 CH 2 O) 3-6 (NR 4c R 4d ), (—C 1 , C 2 or C 4 alkyl)NR 4c R 4d , —(C 0 -C 4 alkyl)-aryl, —(C 0 -C 4 alkyl)-heteroaryl, —(C 0 -C 4 alkyl)-cycloalkyl, or —(C 0 , C 1 or C 4 alkyl)-heterocycloalkyl,

R 4b is hydrogen, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, —OR 4c , —(C 1 , C 2 or C 4 alkyl)OR 4c , —(C 0 -C 4 alkyl)-C(O)(C 1 -C 4 alkyl), —(C 0 -C 4 alkyl)-C(O)O(R 4c ), —(C 0 -C 4 alkyl)CN, —(CH 2 CH 2 O) 0-6 (C 1 -C 8 alkyl), —(CH 2 CH 2 O) 3-6 (NR 4c R 4d ), —(C 1 , C 2 or C 4 alkyl)NR 4c R 4d , —(C 0 -C 4 alkyl)-aryl, —(C 0 -C 4 alkyl)-heteroaryl, —(C 0 -C 4 alkyl)-cycloalkyl, or —(C 0 , C 1 or C 4 alkyl)-heterocycloalkyl,

wherein R 4c and R 4d are hydrogen or C 1 -C 6 alkyl,

or R 4a and R 4b together with a nitrogen to which they are attached form a heterocycloalkyl or heteroaryl ring,

R 4c is hydrogen, C 1 -C 8 alkyl, cycloalkyl or aryl,

R 4f is —OR 4g , C 1 -C 8 alkyl, cycloalkyl or NR 4h R 4i ,

wherein R 49 is C 1 -C 8 alkyl, cycloalkyl, or aryl, and

wherein R 4h and R 4i are C 1 -C 8 alkyl, or R 4h and R 4i together with a nitrogen to which they are attached form a heterocyloalkyl ring or heteroaryl ring, and

R 4j and R 4k are each independently hydrogen or C 1 -C 8 alkyl;

R 5 is hydrogen, C 1 -C 8 alkyl, —(C 1 -C 4 alkyl)-O—(C 1 -C 4 alkyl), —C(O)(C 1 -C 4 alkyl), —C(O)O(C 1 -C 4 alkyl), —C(O)NH 2 , —C(O)NH(C 1 -C 4 alkyl), —C(O)N(C 1 -C 4 alkyl) 2 , —(C 1 -C 4 alkyl)C(O)O(C 1 -C 4 alkyl), or —(C 1 -C 4 alkyl)OC(O)(C 1 -C 4 alkyl);

R 6 is —OR 6a , wherein R 6a is hydrogen, —(C 1 -C 4 alkyl)-O—(C 1 -C 4 alkyl), —C(O)(C 1 -C 4 alkyl), —C(O)O(C 1 -C 4 alkyl), —C(O)NH 2 , —C(O)NH(C 1 -C 4 alkyl), —C(O)N(C 1 -C 4 alkyl) 2 , —(C 1 -C 4 alkyl)C(O)O(C 1 -C 4 alkyl), or —(C 1 -C 4 alkyl)OC(O)(C 1 -C 4 alkyl); and

R 7 is hydrogen,

provided R 7 is not hydrogen when R 4 is hydrogen, wherein

Q 2 is O or S;

R 7a is hydrogen, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, —OR 7c , —(C 1 -C 4 alkyl)OR 7c , —(C 0 -C 4 alkyl)-C(O)(C 1 -C 4 alkyl), —(C 0 -C 4 alkyl)-C(O)O(R 7c ), —(C 0 -C 4 alkyl)CN, —(CH 2 CH 2 O) 0-6 (C 1 -C 8 alkyl), —(CH 2 CH 2 O) 3-6 (NR 7c R 7d ), —(C 1 , C 2 or C 4 alkyl)NR 7c R 7d , —(C 0 -C 4 alkyl)-aryl, —(C 0 -C 4 alkyl)-heteroaryl, —(C 0 -C 4 alkyl)-cycloalkyl, or —(C 0 , C 1 or C 4 alkyl)-heterocycloalkyl,

R 7b is hydrogen, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, —OR 7c , —(C 1 -C 4 alkyl)OR 7c , —(C 0 -C 4 alkyl)-C(O)(C 1 -C 4 alkyl), —(C 0 -C 4 alkyl)-C(O)O(R 7c ), —(C 0 -C 4 alkyl)CN, —(CH 2 CH 2 O) 0-6 (C 1 -C 8 alkyl), —(CH 2 CH 2 O) 3-6 (NR 7c R 7d ), —(C 1 , C 2 or C 4 alkyl)NR 7c R 7d , —(C 0 -C 4 alkyl)-aryl, —(C 0 -C 4 alkyl)-heteroaryl, —(C 0 -C 4 alkyl)-cycloalkyl, or —(C 0 , C 1 or C 4 alkyl)-heterocycloalkyl,

wherein R 70 and R 7d are hydrogen or C 1 -C 6 alkyl,

or R 7a and R 7h together with a nitrogen to which they are attached form a heterocycloalkyl or heteroaryl ring,

R 7e is H, C 1 -C 8 alkyl, cycloalkyl, or aryl,

R 7f is —OR 7g , C 1 -C 8 alkyl, cycloalkyl, or NR 7h R 7i ,

wherein R 7g is C 1 -C 8 alkyl, cycloalkyl, or aryl, and

wherein R 7h and R 7i are C 1 -C 8 alkyl, or R 7h and R 7i together with a nitrogen to which they are attached form a heterocyloalkyl ring or heteroaryl ring, and

R 7j and R 7k are each independently hydrogen or C 1 -C 8 alkyl;

wherein

each alkyl, alkenyl and alkynyl is unsubstituted, halogenated, substituted with one hydroxyl group, one or two C 1 -C 6 alkoxy groups, one or two —C(O)O(C 1 -C 4 alkyl) groups, or one or two oxo groups;

each cycloalkyl has 3-10 ring carbons and is saturated or partially unsaturated, and optionally includes one or two fused cycloalkyl rings, each fused ring having 3-8 ring members, and is substituted with 0-6 R 8 ;

each heterocycloalkyl has 3-10 ring members and 1-3 heteroatoms where each is independently nitrogen, oxygen or sulfur and is saturated or partially unsaturated, and optionally includes one or two fused cycloalkyl rings, each having 3-8 ring members, and is substituted with 0-6 R 8 ;

each aryl is a phenyl or a naphthyl, and optionally includes one or two fused cycloalkyl or heterocycloalkyl rings, each fused cycloalkyl or heterocycloalkyl ring having 4-8 ring members, and is substituted with 0-5 R 9 ;

each heteroaryl is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms, where each is independently nitrogen, oxygen or sulfur or a 8-10 membered bicyclic heteroaryl having 1-5 heteroatoms where each is independently nitrogen, oxygen or sulfur, and optionally includes one or two fused cycloalkyl or heterocycloalkyl rings, each fused cycloalkyl or heterocycloalkyl ring having 4-8 ring members, and is substituted with 0-5 R 9 ,

in which

each R 8 is independently oxo, C 1 -C 4 alkyl, —Cl, —F, —Br, —CN, —SF 5 , —N 3 , nitro, —SR A , —S(O) 1-2 R A , —OR A , —(C 0 -C 3 alkyl)-OR B , —NR B R A , —C(O)R A , —C(O)NR B R A , —NR B C(O)R A , —C(S)NR B R A , —NR B C(S)R A , —CO 2 R A , —OC(O)R A , —C(O)SR A , —SC(O)R A , —C(S)OR A , —OC(S)R A , —C(S)SR A , —SC(S)R A , —S(O) 1-2 OR A , —OS(O) 1-2 R A , —S(O) 1-2 NR B R A , —NR B S(O) 1-2 R A , —OCO 2 R A , —OC(O)NR B R A , —NR B CO 2 R A , —NR B C(O)NR B R A , —SCO 2 R A , —OC(O)SR A , —SC(O)SR A , —SC(O)NR B R A , —NR B C(O)SR A , —OC(S)OR A , —OC(S)NR B R A , —NR B C(S)OR A , —NR B C(S)NR B R A , —SC(S)OR A , —OC(S)SR A , —SC(S)SR A , —SC(S)NR B R A , —NR B C(S)SR A , —NR B C(NR B )NR B R A , —NR B S(O) 1-2 NR B R A , phenyl, C 3 -C 8 cycloalkyl, a five to six-membered heteroaryl, or a five to six-membered heterocycloalkyl; and

each R 9 is independently optionally-substituted C 1 -C 4 alkyl, —Cl, —F, —Br, —CN, —SF 5 , —N 3 , nitro, —SR A , —S(O) 1-2 R A , —OR A , —(C 0 -C 3 alkyl)-OR B , —NR B R A , —C(O)R A , —C(O)NR B R A , —NR B C(O)R A , —C(S)NR B R A , —NR B C(S)R A , —CO 2 R A , —OC(O)R A , —SO 3 H, —C(O)SR A , —SC(O)R A , —C(S)OR A , —OC(S)R A , —C(S)SR A , —SC(S)R A , —S(O) 1-2 OR A , —OS(O) 1-2 R A , —S(O) 1-2 NR B R A , —NR B S(O) 1-2 R A , —OCO 2 R A , —OC(O)NR B R A , —NR B CO 2 R A , —NR B C(O)NR B R A , —SCO 2 R A , —OC(O)SR A , —SC(O)SR A , —SC(O)NR B R A , —NR B C(O)SR A , —OC(S)OR A , —OC(S)NR B R A , —NR B C(S)OR A , —NR B C(S)NR B R A , —SC(S)OR A , —OC(S)SR A , —SC(S)SR A , —SC(S)NR B R A , —NR B C(S)SR A , —NR B C(NR B )NR B R A , —NR B S(O) 1-2 NR B R A , phenyl, C 3 -C 8 cycloalkyl, a five to six-membered heteroaryl, or a five to six-membered heterocycloalkyl;

wherein each R A is independently H or C 1 -C 3 alkyl, and each R B is independently H, C 1 -C 3 alkyl, C 1 -C 3 fluoroalkyl, C 1 -C 3 hydroxyalkyl, —S(O) 1-2 (C 1 -C 3 alkyl), —C(O)(C 1 -C 3 alkyl) or —CO 2 (C 1 -C 3 alkyl),

wherein the compound is not

2. The compound according to claim 1 , wherein the moiety

3. The compound according to claim 1 , wherein R 1 is hydrogen, halo, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, —CO 2 H, —(C 0 -C 4 alkyl)-C(O)O(C 1 -C 6 alkyl), —OR 1a , —(C 1 -C 4 alkyl)OR 1a , —SR 1a , —(C 1 -C 4 alkyl)SR 1a , —NR 1b R 1c , —(C 1 -C 4 alkyl)NR 1b R 1c , —(C 1 -C 4 alkyl)C(O)NR 1b R 1c , —(C 0 -C 4 alkyl)-aryl, —(C 0 -C 4 alkyl)-heteroaryl, —(C 0 -C 4 alkyl)-cycloalkyl, —(C 0 -C 4 alkyl)-heterocycloalkyl, or oxo.

4. The compound according to claim 1 , wherein R 2 is hydrogen, halo, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, —CO 2 H, —(C 0 -C 4 alkyl)-C(O)O(C 1 -C 6 alkyl), —OR 2a , —(C 1 -C 4 alkyl)OR 2a , —SR 2a , —(C 1 -C 4 alkyl)SR 2a , —NR 2b R 2c , —(C 1 -C 4 alkyl)NR 2b R 2c , —(C 1 -C 4 alkyl)C(O)NR 2b R 2c , —(C 0 -C 4 alkyl)-aryl, —(C 0 -C 4 alkyl)-heteroaryl, —(C 0 -C 4 alkyl)-cycloalkyl, —(C 0 -C 4 alkyl)-heterocycloalkyl, or oxo.

5. The compound according to claim 1 , wherein R 3 is C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, —(OCH 2 CH 2 ) 0-6 OCH 3 , —(C 0 -C 4 alkyl)-aryl, —(C 0 -C 4 alkyl)-heteroaryl, —(C 0 -C 4 alkyl)-cycloalkyl or —(C 0 -C 4 alkyl)-heterocycloalkyl.

6. The compound according claim 1 , wherein R 5 is hydrogen, C 1 -C 6 alkyl, —(C 1 -C 4 alkyl)-O—(C 1 -C 4 alkyl), —C(O)(C 1 -C 4 alkyl), —C(O)O(C 1 -C 4 alkyl), —C(O)NH 2 , —C(O)NH(C 1 -C 4 alkyl), or —C(O)N(C 1 -C 4 alkyl) 2 .

7. The compound according to claim 1 , wherein R 5 is hydrogen and R 6 is —OH.

8. The compound according to claim 1 , wherein the compound is of formula:

9. The compound according to claim 1 , wherein each alkyl is unsubstituted.

10. A compound or a pharmaceutically acceptable salt, solvate or hydrate thereof selected from the group consisting of:

2,6-dihydroxy-N,3′-dimethyl-4-pentyl-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N-methoxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-carboxamide;

N-ethyl-2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N-isopropyl-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-carboxamide;

N-acetyl-2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-carboxamide;

N-cyclopropyl-2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-carboxamide;

N-cyclopentyl-2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-3′-methyl-4-pentyl-N-(1-(trifluoromethyl)cyclopentyl)-[1,1′-biphenyl]-3-carboxamide;

N-cyclohexyl-2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-3′-methyl-4-pentyl-N-phenyl-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N-(4-methoxyphenyl)-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-3′-methyl-4-pentyl-N-(4-(trifluoromethyl)phenyl)-[1,1′-biphenyl]-3-carboxamide;

N-(2,6-dimethylphenyl)-2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-carboxamide;

N-benzyl-2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-3′-methyl-4-pentyl-N-(pyridin-3-ylmethyl)-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-3′-methyl-4-pentyl-N-(pyrimidin-5-ylmethyl)-[1,1′-biphenyl]-3-carboxamide;

N-(3,4-dimethylisoxazol-5-yl)-2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-3′-methyl-N-(oxazol-5-ylmethyl)-4-pentyl-[1,1′-biphenyl]-3-carboxamide;

N-((1,3,4-oxadiazol-2-yl)methyl)-2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-carboxamide;

N-((1H-tetrazol-5-yl)methyl)-2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-carboxamide;

methyl 2-(2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-ylcarboxamido)acetate;

(S)-methyl 2-(2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-ylcarboxamido)propanoate;

(S)-methyl 2-(2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-ylcarboxamido)-3-phenylpropanoate;

(S)-methyl 2-(2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-ylcarboxamido)-3-(1H-imidazol-5-yl)propanoate;

N-allyl-2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N,N,3′-trimethyl-4-pentyl-[1,1′-biphenyl]-3-carboxamide;

N-cyclopropyl-2,6-dihydroxy-N,3′-dimethyl-4-pentyl-[1,1′-biphenyl]-3-carboxamide;

N-cyclohexyl-2,6-dihydroxy-N,3′-dimethyl-4-pentyl-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N,3′-dimethyl-4-pentyl-N-phenyl-[1,1′-biphenyl]-3-carboxamide;

N-benzyl-2,6-dihydroxy-N,3′-dimethyl-4-pentyl-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N,3′-dimethyl-4-pentyl-N-(pyridin-3-ylmethyl)-[1,1′-biphenyl]-3-carboxamide;

N-((1H-tetrazol-5-yl)methyl)-2,6-dihydroxy-N,3′-dimethyl-4-pentyl-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N-(isoxazol-3-ylmethyl)-N,3′-dimethyl-4-pentyl-[1,1′-biphenyl]-3-carboxamide;

(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)methanone;

(2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)(4-methylpiperazin-1-yl)methanone;

1-(4-(2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-carbonyl)piperazin-1-yl)ethan-1-one;

(2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)(4-(methylsulfonyl)piperazin-1-yl)methanone;

(2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)(1,1-dioxidothiomorpholino)methanone;

(2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)(morpholino)methanone;

methyl (2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-carbonyl)-D-prolinate;

(2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)(pyrrolidin-1-yl)methanone;

1-(2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-carbonyl)pyrrolidin-3-one;

(2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)(isoindolin-2-yl)methanone;

(2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)(1H-indol-1-yl)methanone;

aziridin-1-yl(2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)methanone;

(S)-(2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)(2-methylaziridin-1-yl)methanone;

(R)-(2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)(2-methylaziridin-1-yl)methanone;

azetidin-1-yl(2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)methanone;

(3,3-difluoroazetidin-1-yl)(2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)methanone;

N,N-diethyl-2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-carboxamide;

N-cyano-2,6-dihydroxy-N,3′-dimethyl-4-pentyl-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N-methoxy-N,3′-dimethyl-4-pentyl-[1,1′-biphenyl]-3-carboxamide;

N-allyl-2,6-dihydroxy-N,3′-dimethyl-4-pentyl-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N-(2-methoxyethyl)-N,3′-dimethyl-4-pentyl-[1,1′-biphenyl]-3-carboxamide;

N-(2-(dimethylamino)ethyl)-2,6-dihydroxy-N,3′-dimethyl-4-pentyl-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N,N-bis(2-hydroxyethyl)-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-carboxamide;

N-(2-bromobenzyl)-2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-carboxamide;

methyl ((2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)methyl)(methyl)carbamate;

ethyl ((2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)methyl)(methyl)carbamate;

propyl ((2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)methyl)(methyl)carbamate;

((2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)methyl)(methyl)carbamate;

ethyl ((2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)methyl)(methyl)carbamate;

isopropyl ((2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)methyl)(methyl)carbamate;

cyclopentyl ((2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)methyl)(methyl)carbamate;

cyclohexyl ((2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)methyl)(methyl)carbamate;

phenyl ((2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)methyl)(methyl)carbamate;

methyl ((2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)methyl)carbamate;

methyl ((2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)methyl)(ethyl)carbamate;

methyl cyclopropyl((2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)methyl)carbamate;

cyclopentyl cyclopropyl((2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)methyl)carbamate;

N-((2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)methyl)acetamide;

N-((2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)methyl)cyclopropanecarboxamide;

N-((2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)methyl)cyclopentanecarboxamide;

N-((2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)methyl)cyclohexanecarboxamide;

N-((2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)methyl)-N-methylacetamide;

N-((2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)methyl)-N-methylcyclopropanecarboxamide;

N-((2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)methyl)-N-methylcyclopentanecarboxamide;

N-((2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)methyl)-N-methylcyclohexanecarboxamide;

N-cyclopropyl-N-((2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)methyl)acetamide;

N-((2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)methyl)-N-phenylacetamide;

N-(1-(2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)ethyl)acetamide;

N-(1-(2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)ethyl)-N-methylacetamide;

3-((2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)methyl)-1,1-dimethylurea;

N-((2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)methyl)azetidine-1-carboxamide;

N-((2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)methyl)pyrrolidine-1-carboxamide;

N-((2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)methyl)piperidine-1-carboxamide;

1-((2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)methyl)-1,3,3-trimethylurea;

N-((2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)methyl)-N-methylazetidine-1-carboxamide;

N-((2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)methyl)-N-methylpyrrolidine-1-carboxamide;

N-((2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)methyl)-N-methylpiperidine-1-carboxamide;

3-(1-(2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)ethyl)-1,1-dimethylurea;

1-(1-(2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)ethyl)-1,3,3-trimethylurea;

N-(1-(2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)ethyl)azetidine-1-carboxamide;

N-(1-(2,6-dihydroxy-3′-methyl-4-pentyl-[1,1′-biphenyl]-3-yl)ethyl)-N-methylazetidine-1-carboxamide;

2,6-dihydroxy-N,3′-dimethyl-4-propyl-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N,5′-dimethyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N-methoxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-carboxamide;

N-ethyl-2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N-isopropyl-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-carboxamide;

N-acetyl-2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-carboxamide;

N-cyclopropyl-2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-carboxamide;

N-cyclopentyl-2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-N-(1-(trifluoromethyl)cyclopentyl)-[1,1′-biphenyl]-3-carboxamide;

N-cyclohexyl-2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-5′-methyl-4-pentyl-N-phenyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N-(4-methoxyphenyl)-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-N-(4-(trifluoromethyl)phenyl)-[1,1′-biphenyl]-3-carboxamide;

N-(2,6-dimethylphenyl)-2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-carboxamide;

N-benzyl-2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-N-(pyridin-3-ylmethyl)-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-N-(pyrimidin-5-ylmethyl)-[1,1′-biphenyl]-3-carboxamide;

N-(3,4-dimethylisoxazol-5-yl)-2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-5′-methyl-N-(oxazol-5-ylmethyl)-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-carboxamide;

N-((1,3,4-oxadiazol-2-yl)methyl)-2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-carboxamide;

N-((1H-tetrazol-5-yl)methyl)-2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-carboxamide;

methyl (2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-carbonyl)glycinate;

methyl (2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-carbonyl)-L-alaninate;

methyl (2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-carbonyl)-L-phenylalaninate;

methyl (2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-carbonyl)-L-histidinate;

N-allyl-2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N,N,5′-trimethyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-carboxamide;

N-cyclopropyl-2,6-dihydroxy-N,5′-dimethyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-carboxamide;

N-cyclohexyl-2,6-dihydroxy-N,5′-dimethyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N,5′-dimethyl-4-pentyl-N-phenyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-carboxamide;

N-benzyl-2,6-dihydroxy-N,5′-dimethyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N,5′-dimethyl-4-pentyl-2′-(prop-1-en-2-yl)-N-(pyridin-3-ylmethyl)-[1,1′-biphenyl]-3-carboxamide;

N-((1H-tetrazol-5-yl)methyl)-2,6-dihydroxy-N,5′-dimethyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N-(isoxazol-3-ylmethyl)-N,5′-dimethyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-carboxamide;

(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)methanone;

(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)(4-methylpiperazin-1-yl)methanone;

1-(4-(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-carbonyl)piperazin-1-yl)ethan-1-one;

(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)(4-(methylsulfonyl)piperazin-1-yl)methanone;

(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)(1,1-dioxidothiomorpholino)methanone;

(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)(morpholino)methanone;

methyl (2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-carbonyl)-D-prolinate;

(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)(pyrrolidin-1-yl)methanone;

1-(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-carbonyl)pyrrolidin-3-one;

(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)(isoindolin-2-yl)methanone;

(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)(1H-indol-1-yl)methanone;

aziridin-1-yl(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)methanone;

(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)((S)-2-methylaziridin-1-yl)methanone;

(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)((R)-2-methylaziridin-1-yl)methanone;

azetidin-1-yl(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)methanone;

(3,3-difluoroazetidin-1-yl)(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)methanone;

N,N-diethyl-2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-carboxamide;

N-cyano-2,6-dihydroxy-N,5′-dimethyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N-methoxy-N,5′-dimethyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-carboxamide;

N-allyl-2,6-dihydroxy-N,5′-dimethyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N-(2-methoxyethyl)-N,5′-dimethyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-carboxamide;

N-(2-(dimethylamino)ethyl)-2,6-dihydroxy-N,5′-dimethyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N,N-bis(2-hydroxyethyl)-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-carboxamide;

N-(2-bromobenzyl)-2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-carboxamide;

methyl ((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)methyl)(methyl)carbamate;

ethyl ((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)methyl)(methyl)carbamate;

propyl ((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)methyl)(methyl)carbamate;

isopropyl ((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)methyl)(methyl)carbamate;

neopentyl ((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)methyl)(methyl)carbamate;

ethyl ((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)methyl)carbamate;

cyclopentyl ((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)methyl)(methyl)carbamate;

cyclohexyl ((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)methyl)(methyl)carbamate;

phenyl ((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)methyl)(methyl)carbamate;

methyl ((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)methyl)carbamate;

methyl ((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)methyl)(ethyl)carbamate;

methyl cyclopropyl((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)methyl)carbamate;

cyclopentyl cyclopropyl((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)methyl)carbamate;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)methyl)acetamide;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)methyl)cyclopropanecarboxamide;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)methyl)cyclopentanecarboxamide;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)methyl)cyclohexanecarboxamide;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)methyl)-N-methylacetamide;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)methyl)-N-methylcyclopropanecarboxamide;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)methyl)-N-methylcyclopentanecarboxamide;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)methyl)-N-methylcyclohexanecarboxamide;

N-cyclopropyl-N-((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)methyl)acetamide;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)methyl)-N-phenylacetamide;

N-(1-(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)ethyl)acetamide;

N-(1-(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)ethyl)-N-methylacetamide;

3-((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)methyl)-1,1-dimethylurea;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)methyl)azetidine-1-carboxamide;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)methyl)pyrrolidine-1-carboxamide;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)methyl)piperidine-1-carboxamide;

1-((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)methyl)-1,3,3-trimethylurea;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)methyl)-N-methylazetidine-1-carboxamide;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)methyl)-N-methylpyrrolidine-1-carboxamide;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)methyl)-N-methylpiperidine-1-carboxamide;

3-(1-(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)ethyl)-1,1-dimethylurea;

1-(1-(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)ethyl)-1,3,3-trimethylurea;

N-(1-(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)ethyl)azetidine-1-carboxamide;

N-(1-(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-[1,1′-biphenyl]-3-yl)ethyl)-N-methylazetidine-1-carboxamide;

2,6-dihydroxy-N,5′-dimethyl-2′-(prop-1-en-2-yl)-4-propyl-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N,5′-dimethyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N-methoxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

N-ethyl-2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N-isopropyl-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

N-acetyl-2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

N-cyclopropyl-2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

N-cyclopentyl-2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-5′-methyl-4-pentyl-N-(1-(trifluoromethyl)cyclopentyl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

N-cyclohexyl-2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-5′-methyl-4-pentyl-N-phenyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N-(4-methoxyphenyl)-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-5′-methyl-4-pentyl-N-(4-(trifluoromethyl)phenyl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

N-(2,6-dimethylphenyl)-2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

N-benzyl-2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-5′-methyl-4-pentyl-N-(pyridin-3-ylmethyl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-5′-methyl-4-pentyl-N-(pyrimidin-5-ylmethyl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

N-(3,4-dimethylisoxazol-5-yl)-2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-5′-methyl-N-(oxazol-5-ylmethyl)-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

N-((1,3,4-oxadiazol-2-yl)methyl)-2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

N-((1H-tetrazol-5-yl)methyl)-2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

methyl 2-(2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-ylcarboxamido)acetate;

(2S)-methyl 2-(2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-ylcarboxamido)propanoate;

methyl (2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carbonyl)-L-phenylalaninate;

(2S)-methyl 2-(2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-ylcarboxamido)-3-(1H-imidazol-5-yl)propanoate;

N-allyl-2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N,N,5′-trimethyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

N-cyclopropyl-2,6-dihydroxy-N,5′-dimethyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

N-cyclohexyl-2,6-dihydroxy-N,5′-dimethyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N,5′-dimethyl-4-pentyl-N-phenyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

N-benzyl-2,6-dihydroxy-N,5′-dimethyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N,5′-dimethyl-4-pentyl-N-(pyridin-3-ylmethyl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

N-((1H-tetrazol-5-yl)methyl)-2,6-dihydroxy-N,5′-dimethyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N-(isoxazol-3-ylmethyl)-N,5′-dimethyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methanone;

(2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)(4-methylpiperazin-1-yl)methanone;

1-(4-(2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carbonyl)piperazin-1-yl)ethan-1-one;

(2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)(4-(methylsulfonyl)piperazin-1-yl)methanone;

(2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)(1,1-dioxidothiomorpholino)methanone;

(2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)(morpholino)methanone;

methyl (2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carbonyl)-D-prolinate;

(2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)(pyrrolidin-1-yl)methanone;

1-(2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carbonyl)pyrrolidin-3-one;

(2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)(isoindolin-2-yl)methanone;

(2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)(1H-indol-1-yl)methanone;

aziridin-1-yl(2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methanone;

(2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)((S)-2-methylaziridin-1-yl)methanone;

(2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)((R)-2-methylaziridin-1-yl)methanone;

azetidin-1-yl(2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methanone;

(3,3-difluoroazetidin-1-yl)(2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methanone;

N,N-diethyl-2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

N-cyano-2,6-dihydroxy-N,5′-dimethyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N-methoxy-N,5′-dimethyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

N-allyl-2,6-dihydroxy-N,5′-dimethyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N-(2-methoxyethyl)-N,5′-dimethyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

N-(2-(dimethylamino)ethyl)-2,6-dihydroxy-N,5′-dimethyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N,N-bis(2-hydroxyethyl)-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

N-(2-bromobenzyl)-2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

methyl ((2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)(methyl)carbamate;

ethyl ((2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)(methyl)carbamate;

propyl ((2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)(methyl)carbamate;

isopropyl ((2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)(methyl)carbamate;

neopentyl ((2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)(methyl)carbamate;

ethyl ((2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)carbamate;

cyclopentyl ((2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)(methyl)carbamate;

cyclohexyl ((2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)(methyl)carbamate;

phenyl ((2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)(methyl)carbamate;

methyl ((2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)carbamate;

methyl ((2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)(ethyl)carbamate;

methyl cyclopropyl((2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)carbamate;

cyclopentyl cyclopropyl((2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)carbamate;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)acetamide;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)cyclopropanecarboxamide;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)cyclopentanecarboxamide;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)cyclohexanecarboxamide;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)-N-methylacetamide;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)-N-methylcyclopropanecarboxamide;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)-N-methylcyclopentanecarboxamide;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)-N-methylcyclohexanecarboxamide;

N-cyclopropyl-N-((2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)acetamide;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)-N-phenylacetamide;

N-(1-(2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)ethyl)acetamide;

N-(1-(2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)ethyl)-N-methylacetamide;

3-((2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)-1,1-dimethylurea;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)azetidine-1-carboxamide;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)pyrrolidine-1-carboxamide;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)piperidine-1-carboxamide;

1-((2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)-1,3,3-trimethylurea;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)-N-methylazetidine-1-carboxamide;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)-N-methylpyrrolidine-1-carboxamide;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)-N-methylpiperidine-1-carboxamide;

3-(1-(2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)ethyl)-1,1-dimethylurea;

1-(1-(2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)ethyl)-1,3,3-trimethylurea;

N-(1-(2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)ethyl)azetidine-1-carboxamide;

N-(1-(2,6-dihydroxy-5′-methyl-4-pentyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)ethyl)-N-methylazetidine-1-carboxamide;

2,6-dihydroxy-N,5′-dimethyl-4-propyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N,5′-dimethyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N-methoxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

N-ethyl-2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N-isopropyl-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

N-acetyl-2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

N-cyclopropyl-2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

N-cyclopentyl-2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-N-(1-(trifluoromethyl)cyclopentyl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

N-cyclohexyl-2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-5′-methyl-4-pentyl-N-phenyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N-(4-methoxyphenyl)-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-N-(4-(trifluoromethyl)phenyl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

N-(2,6-dimethylphenyl)-2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

N-benzyl-2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-N-(pyridin-3-ylmethyl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-N-(pyrimidin-5-ylmethyl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

N-(3,4-dimethylisoxazol-5-yl)-2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-5′-methyl-N-(oxazol-5-ylmethyl)-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

N-((1,3,4-oxadiazol-2-yl)methyl)-2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

N-((1H-tetrazol-5-yl)methyl)-2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

methyl 2-(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-ylcarboxamido)acetate;

(S)-methyl 2-(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-ylcarboxamido)propanoate;

(S)-methyl 2-(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-ylcarboxamido)-3-phenylpropanoate;

(S)-methyl 2-(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-ylcarboxamido)-3-(1H-imidazol-5-yl)propanoate;

N-allyl-2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N,N,5′-trimethyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

N-cyclopropyl-2,6-dihydroxy-N,5′-dimethyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

N-cyclohexyl-2,6-dihydroxy-N,5′-dimethyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N,5′-dimethyl-4-pentyl-N-phenyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

N-benzyl-2,6-dihydroxy-N,5′-dimethyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N,5′-dimethyl-4-pentyl-2′-(prop-1-en-2-yl)-N-(pyridin-3-ylmethyl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

N-((1H-tetrazol-5-yl)methyl)-2,6-dihydroxy-N,5′-dimethyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N-(isoxazol-3-ylmethyl)-N,5′-dimethyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methanone;

(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)(4-methylpiperazin-1-yl)methanone;

1-(4-(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carbonyl)piperazin-1-yl)ethan-1-one;

(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)(4-(methylsulfonyl)piperazin-1-yl)methanone;

(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)(1,1-dioxidothiomorpholino)methanone;

(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)(morpholino)methanone;

methyl (2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carbonyl)-D-prolinate;

(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)(pyrrolidin-1-yl)methanone;

1-(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carbonyl)pyrrolidin-3-one;

(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)(isoindolin-2-yl)methanone;

(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)(1H-indol-1-yl)methanone;

aziridin-1-yl(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methanone;

(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)((S)-2-methylaziridin-1-yl)methanone;

(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)((R)-2-methylaziridin-1-yl)methanone;

azetidin-1-yl(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methanone;

(3,3-difluoroazetidin-1-yl)(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methanone;

N,N-diethyl-2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

N-cyano-2,6-dihydroxy-N,5′-dimethyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N-methoxy-N,5′-dimethyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

N-allyl-2,6-dihydroxy-N,5′-dimethyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N-(2-methoxyethyl)-N,5′-dimethyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

N-(2-(dimethylamino)ethyl)-2,6-dihydroxy-N,5′-dimethyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-N,N-bis(2-hydroxyethyl)-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

N-(2-bromobenzyl)-2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide;

methyl ((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)(methyl)carbamate;

ethyl ((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)(methyl)carbamate;

propyl ((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)(methyl)carbamate;

isopropyl ((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)(methyl)carbamate;

neopentyl ((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)(methyl)carbamate;

ethyl ((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)carbamate;

cyclopentyl ((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)(methyl)carbamate;

cyclohexyl ((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)(methyl)carbamate;

phenyl ((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)(methyl)carbamate;

methyl ((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)carbamate;

methyl ((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)(ethyl)carbamate;

methyl cyclopropyl((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)carbamate;

cyclopentyl cyclopropyl((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)carbamate;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)acetamide;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)cyclopropanecarboxamide;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)cyclopentanecarboxamide;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)cyclohexanecarboxamide;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)-N-methylacetamide;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)-N-methylcyclopropanecarboxamide;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)-N-methylcyclopentanecarboxamide;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)-N-methylcyclohexanecarboxamide;

N-cyclopropyl-N-((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)acetamide;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)-N-phenylacetamide;

N-(1-(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)ethyl)acetamide;

N-(1-(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)ethyl)-N-methylacetamide;

3-((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)-1,1-dimethylurea;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)azetidine-1-carboxamide;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)pyrrolidine-1-carboxamide;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)piperidine-1-carboxamide;

1-((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)-1,3,3-trimethylurea;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)-N-methylazetidine-1-carboxamide;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)-N-methylpyrrolidine-1-carboxamide;

N-((2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)methyl)-N-methylpiperidine-1-carboxamide;

3-(1-(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)ethyl)-1,1-dimethylurea;

1-(1-(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)ethyl)-1,3,3-trimethylurea;

N-(1-(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)ethyl)azetidine-1-carboxamide;

N-(1-(2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-yl)ethyl)-N-methylazetidine-1-carboxamide;

2,6-dihydroxy-N,5′-dimethyl-2′-(prop-1-en-2-yl)-4-propyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxamide; and

dimethyl ((2,6-dihydroxy-5′-methyl-4-propyl-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3,5-diyl)bis(methylene))bis(methylcarbamate).

11. A pharmaceutical composition comprising a compound of claim 1 or an enantiomer, diastereomer, racemate, or tautomer thereof, or a pharmaceutically acceptable salt, solvate or hydrate of the compound, enantiomer, diastereomer, racemate, or tautomer, together with a pharmaceutically acceptable excipient, diluent, or carrier.

12. A method of treating a disease associated with a cannabinoid receptor in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound according to claim 1 .

13. A method of treating a disease associated with a cannabinoid receptor in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound according to claim 1 , wherein the disease is acute pain, ADHD/ADD, alcohol use disorder, allergic asthma, ALS, Alzheimer's, anorexia, anxiety disorders, social anxiety disorder, specific phobia, test anxiety, generalized anxiety disorder, arthritis, atherosclerosis, autism, bipolar disorder, burns, cancer, cancer pain, Charcot-Marie-Tooth disease, chronic inflammatory demyelinating polyneuropathies, chronic pain, chronic allograft nephropathy, cocaine use disorder, complex regional pain syndrome, congestive heart failure, depression, fibromyalgia, fragile X syndrome/FXTAS, frontotemporal dementias, gingivitis pyrexia, glaucoma, glioblastoma, glomerulonephropathy, Huntington's disease, hypertrophic scars, IBD/IBS, inflammation, Inflammatory myopathies, ischemia, kidney fibrosis, keloids, leukodystrophies, liver fibrosis, liver cirrhosis, lung fibrosis, migraine, multiple sclerosis, myocardial infarction, nausea, CINV, motion sickness, neuropathic pain, postherpetic neuralgia, painful diabetic neuropathy, nightmare disorder, non-alcoholic fatty liver disease, obesity, obsessive-compulsive disorder, opioid sparing, opioid use disorder, osteoarthritis, osteoporosis, Parkinson's, post-concussion syndrome/traumatic brain injury, psychosis/schizophrenia, PTSD, regulation of bone mass, REM sleep behaviour disorder, reperfusion injury, Rett syndrome, rheumatoid arthritis, skin conditions, acne, psoriatic arthritis, sleep disorders, insomnia, RLS, spinocerebellar ataxias, systemic fibrosis, systemic sclerosis, thermal injury, tobacco use disorder/nicotine dependence, Tourette's, tumors, or trigeminal neuralgia.

14. A method of treating a disease associated with a cannabinoid receptor in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount thereof or a pharmaceutically acceptable salt, solvate or hydrate of a compound according to claim 10 .

15. A method of treating a disease associated with a cannabinoid receptor in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount thereof or a pharmaceutically acceptable salt, solvate or hydrate of a compound according to claim 10 , wherein the disease is acute pain, ADHD/ADD, alcohol use disorder, allergic asthma, ALS, Alzheimer's, anorexia, anxiety disorders, social anxiety disorder, specific phobia, test anxiety, generalized anxiety disorder, arthritis, atherosclerosis, autism, bipolar disorder, burns, cancer, cancer pain, Charcot-Marie-Tooth disease, chronic inflammatory demyelinating polyneuropathies, chronic pain, chronic allograft nephropathy, cocaine use disorder, complex regional pain syndrome, congestive heart failure, depression, fibromyalgia, fragile X syndrome/FXTAS, frontotemporal dementias, gingivitis pyrexia, glaucoma, glioblastoma, glomerulonephropathy, Huntington's disease, hypertrophic scars, IBD/IBS, inflammation, Inflammatory myopathies, ischemia, kidney fibrosis, keloids, leukodystrophies, liver fibrosis, liver cirrhosis, lung fibrosis, migraine, multiple sclerosis, myocardial infarction, nausea, CINV, motion sickness, neuropathic pain, postherpetic neuralgia, painful diabetic neuropathy, nightmare disorder, non-alcoholic fatty liver disease, obesity, obsessive-compulsive disorder, opioid sparing, opioid use disorder, osteoarthritis, osteoporosis, Parkinson's, post-concussion syndrome/traumatic brain injury, psychosis/schizophrenia, PTSD, regulation of bone mass, REM sleep behaviour disorder, reperfusion injury, Rett syndrome, rheumatoid arthritis, skin conditions, acne, psoriatic arthritis, sleep disorders, insomnia, RLS, spinocerebellar ataxias, systemic fibrosis, systemic sclerosis, thermal injury, tobacco use disorder/nicotine dependence, Tourette's, tumors, or trigeminal neuralgia.

16. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt, solvate or hydrate thereof claim 10 and a pharmaceutically acceptable excipient, diluent, or carrier.

17. A method of treating a disease associated with a cannabinoid receptor in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition according to claim 11 .

18. A method of treating a disease associated with a cannabinoid receptor in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition according to claim 11 , wherein the disease is acute pain, ADHD/ADD, alcohol use disorder, allergic asthma, ALS, Alzheimer's, anorexia, anxiety disorders, social anxiety disorder, specific phobia, test anxiety, generalized anxiety disorder, arthritis, atherosclerosis, autism, bipolar disorder, burns, cancer, cancer pain, Charcot-Marie-Tooth disease, chronic inflammatory demyelinating polyneuropathies, chronic pain, chronic allograft nephropathy, cocaine use disorder, complex regional pain syndrome, congestive heart failure, depression, fibromyalgia, fragile X syndrome/FXTAS, frontotemporal dementias, gingivitis pyrexia, glaucoma, glioblastoma, glomerulonephropathy, Huntington's disease, hypertrophic scars, IBD/IBS, inflammation, Inflammatory myopathies, ischemia, kidney fibrosis, keloids, leukodystrophies, liver fibrosis, liver cirrhosis, lung fibrosis, migraine, multiple sclerosis, myocardial infarction, nausea, CINV, motion sickness, neuropathic pain, postherpetic neuralgia, painful diabetic neuropathy, nightmare disorder, non-alcoholic fatty liver disease, obesity, obsessive-compulsive disorder, opioid sparing, opioid use disorder, osteoarthritis, osteoporosis, Parkinson's, post-concussion syndrome/traumatic brain injury, psychosis/schizophrenia, PTSD, regulation of bone mass, REM sleep behaviour disorder, reperfusion injury, Rett syndrome, rheumatoid arthritis, skin conditions, acne, psoriatic arthritis, sleep disorders, insomnia, RLS, spinocerebellar ataxias, systemic fibrosis, systemic sclerosis, thermal injury, tobacco use disorder/nicotine dependence, Tourette's, tumors, or trigeminal neuralgia.

19. A method of treating a disease associated with a cannabinoid receptor in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition according to claim 16 .

20. A method of treating a disease associated with a cannabinoid receptor in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition according to claim 16 , wherein the disease is acute pain, ADHD/ADD, alcohol use disorder, allergic asthma, ALS, Alzheimer's, anorexia, anxiety disorders, social anxiety disorder, specific phobia, test anxiety, generalized anxiety disorder, arthritis, atherosclerosis, autism, bipolar disorder, burns, cancer, cancer pain, Charcot-Marie-Tooth disease, chronic inflammatory demyelinating polyneuropathies, chronic pain, chronic allograft nephropathy, cocaine use disorder, complex regional pain syndrome, congestive heart failure, depression, fibromyalgia, fragile X syndrome/FXTAS, frontotemporal dementias, gingivitis pyrexia, glaucoma, glioblastoma, glomerulonephropathy, Huntington's disease, hypertrophic scars, IBD/IBS, inflammation, Inflammatory myopathies, ischemia, kidney fibrosis, keloids, leukodystrophies, liver fibrosis, liver cirrhosis, lung fibrosis, migraine, multiple sclerosis, myocardial infarction, nausea, CINV, motion sickness, neuropathic pain, postherpetic neuralgia, painful diabetic neuropathy, nightmare disorder, non-alcoholic fatty liver disease, obesity, obsessive-compulsive disorder, opioid sparing, opioid use disorder, osteoarthritis, osteoporosis, Parkinson's, post-concussion syndrome/traumatic brain injury, psychosis/schizophrenia, PTSD, regulation of bone mass, REM sleep behaviour disorder, reperfusion injury, Rett syndrome, rheumatoid arthritis, skin conditions, acne, psoriatic arthritis, sleep disorders, insomnia, RLS, spinocerebellar ataxias, systemic fibrosis, systemic sclerosis, thermal injury, tobacco use disorder/nicotine dependence, Tourette's, tumors, or trigeminal neuralgia.

Assignments (6)

SECURITY INTEREST Recorded Jan 20, 2026

From: CANOPY GROWTH CORPORATION; TWEED INC.

To: JGB COLLATERAL LLC

Reel/Frame 073521/0250 →

RELEASE OF SECURITY INTEREST IN PATENT INTELLECTUAL PROPERTY Recorded Jan 9, 2026

From: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT

To: CANOPY GROWTH CORPORATION

Reel/Frame 074281/0925 →

NOTICE OF GRANT OF SECURITY INTEREST Recorded Aug 15, 2024

From: CANOPY GROWTH CORPORATION

To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT

Reel/Frame 068654/0264 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2023

From: AHMAR, SIAWASH; KIM, JUNG YUN; LAI, PING SHAN; OMEARA, JEFFREY ALAN; TO, QUANG HUY; DOVE, PETER MARTIN

To: DALRIADA DRUG DISCOVERY INC.

Reel/Frame 063599/0715 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2023

From: DALRIADA DRUG DISCOVERY INC.

To: 10607410 CANADA INC.

Reel/Frame 063599/0768 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2023

From: 10607410 CANADA INC.

To: CANOPY GROWTH CORPORATION

Reel/Frame 063599/0796 →

Continuity (3)

Provisional Application 62909363 · Oct 2, 2019

Provisional Application 62966418 · Jan 27, 2020

Related Publication 20220348586A1 · Nov 3, 2022

References Cited (63)

US 6620961B1 · Ikegaya · 2003 [cited by examiner]

US 9670133B2 · Koch et al. · 2017 [cited by applicant]

US 9682079B2 · Schneider · 2017 [cited by examiner]

US 20130209483A1 · McAllister · 2013 [cited by applicant]

US 20190023680A1 · Leahy et al. · 2019 [cited by applicant]

US 20220242844A1 · Omeara et al. · 2022 [cited by applicant]

US 20220242856A1 · Ahmar et al. · 2022 [cited by applicant]

US 20220259221A1 · Omeara et al. · 2022 [cited by applicant]

US 20220259233A1 · Omeara et al. · 2022 [cited by applicant]

US 20220267239A1 · Omeara et al. · 2022 [cited by applicant]

US 20220324806A1 · Ahmar et al. · 2022 [cited by applicant]

US 20220340582A1 · Ahmar et al. · 2022 [cited by applicant]

US 20230024212A1 · Gunning et al. · 2023 [cited by applicant]

US 20230059582A1 · Omeara et al. · 2023 [cited by applicant]

US 20230122510A1 · Ahmar et al. · 2023 [cited by applicant]

US 20230134776A1 · Ahmar et al. · 2023 [cited by applicant]

US 20230150927A1 · Ahmar et al. · 2023 [cited by applicant]

US 20230286906A1 · Ahmar et al. · 2023 [cited by applicant]

CA 3033875 · 2018 [cited by applicant]

JP 2008509965 · 2008 [cited by applicant]

JP 2010500977 · 2010 [cited by applicant]

JP 2011523629 · 2011 [cited by applicant]

JP 2012518645 · 2012 [cited by applicant]

JP 2016531919 · 2016 [cited by applicant]

WO WO03091189 · 2003 [cited by applicant]

WO WO2006018325 · 2006 [cited by applicant]

WO WO2008021849 · 2008 [cited by applicant]

WO WO2008096769 · 2008 [cited by applicant]

WO WO2009135590 · 2009 [cited by applicant]

WO WO2010096650 · 2010 [cited by applicant]

WO WO2014062965 · 2014 [cited by applicant]

WO WO2015009977 · 2015 [cited by applicant]

WO WO2016087649 · 2016 [cited by applicant]

WO WO2018005188 · 2018 [cited by applicant]

WO WO2018035450 · 2018 [cited by applicant]

WO WO2019234728 · 2019 [cited by applicant]

WO WO2020051099 · 2020 [cited by applicant]

WO WO2020107114 · 2020 [cited by applicant]

WO WO2020107119 · 2020 [cited by applicant]

WO WO2020198874A1 · 2020 [cited by examiner]

PubChem CID 78166, National Center for Biotechnology Information. PubChem Compound Summary for CID 78166, Salicylamide, 3-phenyl-. https://pubchem.ncbi.nlm.nih.gov/compound/Salicylamide_-3-phenyl. Accessed Jul. 8, 2023,… [cited by examiner]

Kikuchi et al., Tetrahedron, 68(43), 2012, pp. 8884-8889. (Year: 2012). [cited by examiner]

Sosnicki et al., Journal of Heterocyclic Chemistry (1999), 36(4), 1033-1041. (Year: 1999). [cited by examiner]

PubChem CID 153676242, National Center for Biotechnology Information. “PubChem Compound Summary for CID 153676242, 6-Methyl-3-phenyl-2-propan-2-yloxybenzamide” PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/6-Methyl… [cited by examiner]

PubChem CID 123647558, National Center for Biotechnology Information. “PubChem Compound Summary for CID 123647558, 2-[4-[3-(Dimethylcarbamoyl)-4-(4-hydroxyphenyl)-2-methoxyphenyl]phenyl]acetic acid” PubChem, https://pub… [cited by examiner]

PubChem CID 87069225, National Center for Biotechnology Information. “PubChem Compound Summary for CID 87069225, 2,5-Bis[3,5-bis(trifluoromethyl)phenyl]-4-hydroxybenzene-1,3-dicarboxamide” PubChem, https://pubchem.ncbi.… [cited by examiner]

PubChem CID 21751751 {National Center for Biotechnology Information. “PubChem Compound Summary for CID 21751751, Methyl 3-(2-carbamoyl-3-methoxy-4-phenylphenyl)propanoate” PubChem, https://pubchem.ncbi.nlm.nih.gov/compo… [cited by examiner]

Beadle, A. “CBDA vs CBD: What are the Differences?” [cited by applicant]

Takeda, S. et al. “Cannabidiolic Acid as a Selective Cyclooxygenase-2 Inhibitory Component in Cannabis” [cited by applicant]

Written Opinion in International Application No. PCT/CA2020/051330, Dec. 16, 2020, pp. 1-8. [cited by applicant]

Tong, W. et al. “Derivation of a Pharmacophore Model for Anandamide Using Constrained Conformational Searching and Comparative Molecular Field Analysis” [cited by applicant]

Melvin, L. S. et al. “Structure-Activity Relationships for Cannabinoid Receptor-Binding and Analgesic Activity: Studies of Bicyclic Cannabinoid Analogs” [cited by applicant]

Wiley, J. L. et al. “Resorcinol Derivatives: A Novel Template for the Development of Cannabinoid CB [cited by applicant]

Morales, P. et al. “An Overview on Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol” [cited by applicant]

Cardillo, B. et al. “Alkylation of Resorcinols With Monoterpenoid Allylic Alcohols in Aqueous Acid: Synthesis of New Cannabinoid Derivatives” [cited by applicant]

Vree, T. B. et al. “Identification of Cannabivarins in Hashish by a New Method of Combined Gas Chromatography-Mass-Spectrometry” [cited by applicant]

Extended European Search Report for Application No. EP 20870467.6, Jan. 25, 2023, pp. 1-11. [cited by applicant]

Claims as filed for U.S. Appl. No. 17/780,052, May 26, 2022, pp. 1-12. [cited by applicant]

Kittaka, A. et al., Drug Discovery Science-Medicinal Chemistry, 2007, pp. 142-150 (English translation of Table 7.1 only). [cited by applicant]

Nozaki et al., Drug Discovery Chemistry, First Edition, Dojin Kagaku K.K., 1995, pp. 98-99 (English translation of Table 5.2 only). [cited by applicant]

Anonymous, PubChem CID 104895 (CP55940, CAS 83002-04-4), National Library of Medicine, National Center for Biotechnology Information, created date: Aug. 8, 2005, pp. 1-42. [cited by applicant]

Anonymous, PubChem CID 5282280 (2-AG, CAS 53847-30-6), National Library of Medicine, National Center for Biotechnology Information, created date: Jun. 24, 2005, pp. 1-45. [cited by applicant]

Anonymous, PubChem CID 104849 (Rimonabant, CAS 158681-13-1), National Library of Medicine, National Center for Biotechnology Information, created date: Aug. 8, 2005, pp. 1-29. [cited by applicant]